In silico approach for the identification of immunological properties of enolase from Trypanosoma cruzi and its possible usefulness as vaccine in Chagas disease

Carabarín-Lima, Alejandro; Rodríguez-Morales, Olivia; González-Vázquez, María Cristina; Baylón-Pacheco, Lidia; Reyes, Pedro A.; Arce-Fonseca, Minerva; Rosales‐Encina, José Luis

doi:10.1007/s00436-013-3737-0

Cited by 6 publications

(14 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous work, we cloned the enolase gene sequence into the pRSETB vector and purified the recombinant rTcENO protein [ 36 ]. In this report, we immunized mice with the recombinant rTcENO protein to produce polyclonal antibodies.…”

Section: Resultsmentioning

confidence: 99%

“…The recombinant protein rTcENO was obtained as previously described [ 36 ] and the purified rTcENO did not contain detectable levels of endotoxin contamination as measured by the E-Toxate assay (Sigma, St. Louis, MO, USA). Female BALB/c mice (6–8 weeks old) were immunized with10 μ g/mouse.…”

Section: Methodsmentioning

confidence: 99%

“…The gene encoding TcENO (GenBank access number: KC862322) was obtained from the pRSETB-TcENO plasmid [ 36 ] as a 1.1 kb Kpn I/Hind III (New England Biolabs) fragment. This fragment was subcloned into the prokaryotic/eukaryotic expression vector pBK-CMV (InvitrogenTM by Life Technologies) to generate the pBKTcENO plasmid.…”

Section: Methodsmentioning

confidence: 99%

“…Previously, we cloned and sequenced the gene encoding enolase from T. cruzi and performed immunological in silico assays. Our data showed that the resulting sequence had several predicted peptides for B cells and cytotoxic T lymphocytes (CTL), which suggested that enolase could be a good immunogen [ 36 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Recombinant Enolase of Trypanosoma cruzi as a Novel Vaccine Candidate against Chagas Disease in a Mouse Model of Acute Infection

Arce-Fonseca

González-Vázquez

Rodríguez-Morales

et al. 2018

Journal of Immunology Research

Self Cite

View full text Add to dashboard Cite

Trypanosoma cruzi is the protozoan parasite that causes Chagas disease, which is considered by the World Health Organization to be a neglected tropical disease. Two drugs exist for the treatment of Chagas disease, nifurtimox and benznidazole; they are only effective in the acute phase, and a vaccine is currently not available. In this study, we used the recombinant enolase from T. cruzi H8 strain (MHOM/MX/1992/H8 Yucatán) (rTcENO) and its encoding DNA (pBKTcENO) to immunize mice and evaluate their protective effects in an experimental murine model of acute phase infection. Our results showed that mice vaccinated with rTcENO or its encoding DNA were able to generate typical specific antibodies (IgG1, IgG2a, and IgG2b), suggesting that a mixed Th1/Th2 immune response was induced. The parasite burden in the blood was reduced to 69.8% and 71% in mice vaccinated with rTcENO and pBKTcENO, respectively. The group vaccinated with rTcENO achieved 75% survival, in contrast to the group vaccinated with pBKTcENO that showed no survival in comparison to the control groups. Moreover, rTcENO immunization elevated the production of IFN-γ and IL-2 after the parasite challenge, suggesting that the Th1-type immune response was polarized. These results indicated that rTcENO could be used as a vaccine against Chagas disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Recombinant Enolase of Trypanosoma cruzi as a Novel Vaccine Candidate against Chagas Disease in a Mouse Model of Acute Infection

Arce-Fonseca

González-Vázquez

Rodríguez-Morales

et al. 2018

Journal of Immunology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another application where the ELA assay to detect biomarkers could be of use is the development of vaccines for CD [36] – [38] . Biomarker presence, detected by ELA assays, in parasite challenged vaccinated animals could indicate that the immune response was not sufficient to control the infection.…”

Section: Discussionmentioning

confidence: 99%

Aptamer-Based Detection of Disease Biomarkers in Mouse Models for Chagas Drug Discovery

et al. 2015

View full text Add to dashboard Cite

Drug discovery initiatives, aimed at Chagas treatment, have been hampered by the lack of standardized drug screening protocols and the absence of simple pre-clinical assays to evaluate treatment efficacy in animal models. In this study, we used a simple Enzyme Linked Aptamer (ELA) assay to detect T. cruzi biomarker in blood and validate murine drug discovery models of Chagas disease. In two mice models, Apt-29 ELA assay demonstrated that biomarker levels were significantly higher in the infected group compared to the control group, and upon Benznidazole treatment, their levels reduced. However, biomarker levels in the infected treated group did not reduce to those seen in the non-infected treated group, with 100% of the mice above the assay cutoff, suggesting that parasitemia was reduced but cure was not achieved. The ELA assay was capable of detecting circulating biomarkers in mice infected with various strains of T. cruzi parasites. Our results showed that the ELA assay could detect residual parasitemia in treated mice by providing an overall picture of the infection in the host. They suggest that the ELA assay can be used in drug discovery applications to assess treatment efficacy in-vivo.

show abstract

Enolase from Trypanosoma cruzi is inhibited by its interaction with metallocarboxypeptidase-1 and a putative acireductone dioxygenase

Quintero-Troconis

Buelvas

Carrasco-López

et al. 2018

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

View full text Add to dashboard Cite

In silico approach for the identification of immunological properties of enolase from Trypanosoma cruzi and its possible usefulness as vaccine in Chagas disease

Cited by 6 publications

References 46 publications

Recombinant Enolase of Trypanosoma cruzi as a Novel Vaccine Candidate against Chagas Disease in a Mouse Model of Acute Infection

Recombinant Enolase of Trypanosoma cruzi as a Novel Vaccine Candidate against Chagas Disease in a Mouse Model of Acute Infection

Aptamer-Based Detection of Disease Biomarkers in Mouse Models for Chagas Drug Discovery

Enolase from Trypanosoma cruzi is inhibited by its interaction with metallocarboxypeptidase-1 and a putative acireductone dioxygenase

Contact Info

Product

Resources

About